Amicus Therapeutics was founded in small-town new Jersey in 2002, only five years later becoming publicly traded. The biopharmaceutical agency is so promising because it deals with cures of rare, “orphan” diseases that aren’t targeted by most other drug makers, meaning that the cures that Amicus Therapeutics comes up with will be patented for long periods of time, effectively holding a monopoly over the particular niche it created a treatment for.
Virtually every company has something for sale, whether it’s a product, service, or simply advice, as consulting firms offer (https://www.indeed.com/q-Amicus-Therapeutics-l-Cranbury,-NJ-jobs.html). This sentiment holds especially true for entities that are publicly traded on stock exchanges. Believe it or not, Amicus Therapeutics has zero products for sale right now, although its leading drug, migalastat, is currently in the last stages of development. Migalastat is designed specifically for treating people that have Fabry disease, characterized by cells growing very large and causing problems like pain, premature death, and skin rashes.
Another drug that Amicus Therapeutics is developing is SD-101, which could very well be the first treatment for epidermolysis bulls, a rare genetic disorder that causes countless problems in everyday life occurring from bad skin that’s fragile, weak, and painful. Both of these drugs made by Amicus Therapeutics are in the final stages of creation, expected to hit the market within the next few years.
CHART, a treatment for Fabry disease, lysosomal storage disorders, and Pompe disease, stands for Chaperone-Advanced Replacement Therapy, classified as a novel enzyme replacement therapy. CHART is currently named ATB200/AT2221, and is the basic platform that both of the above cures rests on. This platform is broad enough to have other drugs created from it, far more than the two it currently supports.
Amicus Therapeutics is a highly successful company despite not currently selling any products, or even having the capacity to manufacture drugs on their own. The drugmaker currently has just over 100 employees and maintains its operation on financing from other pharmaceutical companies in exchange for giving them exclusive rights to manufacture their drugs, whenever they’re finished. John Crowely has been the CEO since 2005, helping maneuver contracts into Amicus Therapeutics’ grasp time after time.